Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis

AIMS/INTRODUCTION: To assess the effect of dulaglutide (DU) 1.5/0.75 mg in comparison with glimepiride (GLIM) or insulin glargine (GLAR) on the composite end‐point in Chinese type 2 diabetes patients. MATERIALS AND METHODS: Post‐hoc analyses of two randomized phase III trials (NCT01644500 and NCT016...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xinhua, Wang, Changjiang, Lai, Xiaoyang, Zhang, Bin, Gu, Liqun, Hou, Jianing, Zhou, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232276/
https://www.ncbi.nlm.nih.gov/pubmed/31758850
http://dx.doi.org/10.1111/jdi.13187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232276/
https://www.ncbi.nlm.nih.gov/pubmed/31758850
http://dx.doi.org/10.1111/jdi.13187

Ejemplares similares